TraMetinib CAS NO.871700-17-3

trametinib (gsk1120212) is a kind of high specificity, effective mek1/2 inhibitor, ic50 was 0.92 nm and 1.8 nm, the c - raf, b - raf, erk1/2 no inhibitory activity

trametinib (gsk1120212; jtp 74057) is a highly specific and potent mek1/2 inhibitor with ic50 of 0.92 nm/1.8 nm, no inhibition of the kinase activities of c-raf, b-raf, erk1/2.
ic50 value: 0.92 nm/1.8 nm (mek1/2) [1]
target: mek1/2
in vitro: gsk1120212 inhibits the phosphorylation of mbp regardless of the isotype of raf and mek, with ic50 ranging from 0.92 nm to 3.4 nm. gsk1120212 demonstrates no inhibition of the kinase activities of c-raf, b-raf, erk1 and erk2. in addition, gsk1120212 does not show drastic inhibitory activity against the other 98 kinases. gsk1120212 displays potent inhibitory activity against human colorectal cancer cell lines. ht-29 and colo205 cells, which are known to have a constitutively active b-raf mutant, are most sensitive to gsk1120212 with ic50 0.48 nm and 0.52 nm, respectively [1]. gsk1120212 blocks tumor necrosis factor-α and interleukin-6 production from peripheral blood mononuclear cells (pbmcs) [2].
in vivo: oral administration of gsk1120212 at 0.3 mg/kg or 1 mg/kg once daily for 14 days is effective in inhibiting the ht-29 xenograft growth, and 1 mg/kg of gsk1120212 almost completely blocks the tumor increase. the phosphorylation of erk1/2 is completely inhibited in the established tumor tissues by single oral dose of 1 mg/kg gsk1120212, and both p15ink4b and p27kip1 protein levels are upregulated after 14 days of treatment with gsk1120212. in the colo205 xenograft model, tumor regression is observed even at a dose of 0.3 mg/kg. at a dose of 1 mg/kg, a complete regression is obtained in 4 out of 6 mice in which the tumor degenerates to the point that tumor volume is not measurable [1]. administration of gsk1120212 at 0.1 mg/kg almost completely suppresses adjuvant-induced arthritis (aia) and type ii collagen-induced arthritis (cia) in lewis rats or dba1/j mice, respectively [2].